NCT01251874View on ClinicalTrials.gov

Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

November 22, 2010

Primary Completion Date

September 30, 2024

Study Completion Date

November 20, 2025

Conditions
Recurrent Breast CarcinomaStage IIIB Breast Cancer AJCC v7Stage IIIC Breast Cancer AJCC v7Stage IV Breast Cancer AJCC v6 and v7Triple-Negative Breast Carcinoma
Interventions
PROCEDURE

Biospecimen Collection

Undergo collection of blood sample

DRUG

Carboplatin

Given IV

PROCEDURE

Computed Tomography

Undergo PET/CT

OTHER

Fluorothymidine F-18

Given FLT

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

DRUG

Veliparib

Given PO

Trial Locations (3)

10461

Montefiore Medical Center-Einstein Campus, The Bronx

10467

Montefiore Medical Center - Moses Campus, The Bronx

43210

Ohio State University Comprehensive Cancer Center, Columbus

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH